The
mutual effects recognised at molecular level between
LABAs and ICSs are particularly
important to explain the additive/synergistic effects
of the two drug classes in the treatment of asthma
and COPD.
The molecular interactions between ICSs and LABAs
are schematised in Figure 9: in particular, corticosteroids increase the expression
of β2-receptors and protect them against down-regulation
in response to long-term β2-agonist exposure, whereas β2-agonists may enhance
the anti-inflammatory actions of corticosteroids.
Thus each class of drug enhances
the others beneficial actions.7
Figure 9: Interaction of corticosteroids and β2-agonists.7
|
